CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Hold” by Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has been given a consensus rating of “Hold” by the twenty-two analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $67.85.

A number of brokerages recently issued reports on CRSP. Wedbush dropped their target price on CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 5th. Robert W. Baird decreased their price target on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Friday. Needham & Company LLC restated a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total value of $3,613,800.00. Following the transaction, the chief executive officer owned 134,201 shares in the company, valued at approximately $8,082,926.23. This represents a 30.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of large investors have recently bought and sold shares of CRSP. Royal Bank of Canada lifted its holdings in shares of CRISPR Therapeutics by 28.2% in the first quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock worth $4,856,000 after acquiring an additional 31,392 shares during the last quarter. AQR Capital Management LLC bought a new position in CRISPR Therapeutics in the 1st quarter valued at approximately $861,000. Woodline Partners LP boosted its position in CRISPR Therapeutics by 34.3% in the first quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock valued at $4,645,000 after buying an additional 34,883 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in CRISPR Therapeutics by 26.9% in the second quarter. Janney Montgomery Scott LLC now owns 13,585 shares of the company’s stock valued at $661,000 after buying an additional 2,882 shares in the last quarter. Finally, PFG Investments LLC grew its stake in shares of CRISPR Therapeutics by 23.9% during the second quarter. PFG Investments LLC now owns 12,896 shares of the company’s stock worth $627,000 after buying an additional 2,487 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Down 6.4%

CRISPR Therapeutics stock opened at $49.96 on Friday. The business’s 50-day simple moving average is $55.08 and its 200 day simple moving average is $58.28. The stock has a market cap of $4.76 billion, a price-to-earnings ratio of -8.94 and a beta of 1.70. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.15. The firm had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. As a group, sell-side analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.